Tools chosen: kalshi_direct kalshi_related polymarket_related claude_news gdelt_news wikipedia code_execution

Sub-questions (Fermi decomposition)

Planner reasoning

This is a Kalshi health market on whether US measles cases will average at least 5000/year from 2025-2028. Key drivers are the actual 2025 case count (a record year since 2000), CDC surveillance trends, vaccination rate trajectories under the current administration's health policy, and historical base rates. The Kalshi price is the primary anchor, and simple math can show what future years must produce given 2025's total.

# Current state As of late August 2026 (latest data point), 2026 measles cases have already surpassed the full-year 2025 total, running at ~2,777 YTD (Aug 20) with the year projected to finish in the 3,500–4,500 range. The market resolves on the 2025–2028 **average**, not any single year; with 2025 actual at ~2,200–2,289 cases, hitting a 5,000/year average would require 2027–2028 to run several multiples above any historical US measles year since elimination in 2000. # Timeline of key events - 2025-01 to 2025-08: Southwest US (Texas/Gaines County-centered) measles outbreak spreads to NM, OK, KS; declared over 2025-08-18. Confirmed (Wikipedia/CDC). - 2025-12/2026-01: CDC finalizes 2025 total — reported as 2,144 (AAP) or 2,289 (Wikipedia/CIDRAP/CDC), across 44-45 jurisdictions, ~48-49 outbreaks; highest since 1992. Confirmed, minor source discrepancy on exact figure. - 2026-07-06 to 2026-07-26: 2026 cases climb from 2,170 to 2,318, surpassing all of 2025; described as worst year in 35 years. Confirmed (CDC/medicaldaily/CIDRAP). - 2026-08-17/19: CDC reports kindergarten MMR coverage fell to 92.4% (from 95.2% in 2019-20); exemptions hit record 4.2%. Confirmed (CDC/CNBC/KFF). - 2026-08-20: 2026 YTD reaches 2,777 confirmed cases. Confirmed (AAP Red Book). - 2026-08-25: Two measles deaths reported in Pennsylvania outbreak. Reported (Healio); later noted CDC excluded these from official counts (2026-08-31, Guardian) — rumored/contested classification. - 2026-08-30: Three states reported battling new/active outbreaks. Reported (Yahoo/AP). - 2026 (mid-year): Lancet/CIDRAP analysis states it "highly likely" the US loses measles elimination status in 2026 based on transmission rates >90/10M vs. 1/10M threshold. Reported (CIDRAP/Lancet). # Event Will the average annual US measles case count over 2025–2028 (Trump administration) be at least 5,000? # Outcomes to forecast Yes / No (binary threshold at 5,000 average) # Kalshi market anchor KXAVGMEASLESDJT-29-5000 "At least 5000": **37% YES**, +1% over 7 days, +7% over 30 days, avg daily volume 312 contracts, 40-day range 28–70%. Trending up but off its high of 70%. # Sub-question answers 1. **2025 CDC total / 2026 YTD**: 2025 final ~2,144–2,289 confirmed cases (source discrepancy, both CDC-derived); 2026 YTD as of Aug 20 = 2,777, already exceeding all of 2025. [claude_news, Wikipedia, CIDRAP] 2. **Required 2026-28 average**: Using 2025=~2,289–2,700, the 2026-28 average must be ~5,670–5,830 cases/year (code_execution calc) — 4.4–4.6× the worst historical year (2019, 1,274 cases), sustained for three straight years. 3. **MMR coverage/exemptions**: Kindergarten MMR coverage fell to 92.4% (2025-26) from 95.2% (2019-20); exemptions rose to record 4.2% (from 3.6%), up in 41 states; 39 states below 95% target, 18 below 90%. [CDC/CNBC/KFF] 4. **Active outbreaks/projections**: ~30 active outbreaks mid-2026 (48-49 in 2025); hotspots SC (670-997 cases), Utah (498); PA outbreak with deaths; 3 states reported new outbreaks Aug 2026. Lancet/CIDRAP project US may lose elimination status in 2026; no source projects annual totals reaching 5,000+/year. [CIDRAP, Wikipedia, Yahoo] 5. **Historical base rate**: 0 of 25 years (2000-2024) exceeded 5,000 cases; record is 2019 with 1,274. [code_execution] 6. **Policy factors**: KFF attributes spread to federal/state/local public health funding and staffing cuts, mixed HHS/RFK Jr. messaging, and absence of Senate-confirmed CDC director for most of the period. [KFF] # Key facts (high-confidence, factual) 1. [code_execution] 0/25 years since 2000 exceeded 5,000 cases; 2019 record = 1,274. 2. [Wikipedia/CDC] 2025 total ≈2,289 confirmed cases (45 jurisdictions, 49 outbreaks) — highest since 1992. 3. [AAP Red Book] 2026 YTD (Aug 20) = 2,777, already above full 2025 total. 4. [CDC/CNBC] Kindergarten MMR coverage 92.4% (2025-26 school year), down from 95.2% in 2019-20. 5. [KFF] Exemption rate 4.2%, record high, up in 41 states. # Cross-market signals - Kalshi related: no other measles/vaccination markets found beyond this one. - Polymarket: 0 matching markets on measles/vaccine topics. - Sportsbook implied: N/A (not applicable to health metric). # Analyst opinions and speculation - CIDRAP/Lancet: US "highly likely" to lose measles elimination status in 2026 given transmission rates, but this is a status designation (>12 months continuous transmission), not a case-count magnitude claim. - claude_news synthesis: current trajectory (2,000–3,500/yr range) is "well below" a 5,000/year average threshold unless trends "significantly worsen" — explicit bearish lean on YES. - MSNBC opinion piece: frames cumulative 2025-mid2026 total (~5,000) as exceeding the entire 2000-2024 cumulative total (4,485) — a rhetorical framing, not evidence of hitting a 5,000/year *average*. # Directional lean per outcome - **Yes (≥5,000 avg)**: Supported by accelerating 2026 trend (surpassing 2025 by mid-year), declining vaccination coverage, record exemptions, elimination-status loss risk, ongoing outbreaks in multiple states, funding/messaging headwinds. Opposed by: even best-case 2026 full-year estimate (~4,000-4,500) plus 2025 actual (~2,289) requires 2027-2028 to jointly hit ~26,000+ cases (>13,000/yr each) — 10x the historical record, with zero precedent. - **No (<5,000 avg)**: Strongly supported by 0/25 base rate, magnitude gap (4.5x record needed sustained 3 years), and explicit analyst assessment that current pace implies annual totals far below threshold. # Gaps / unknowns - No explicit epidemiologist point-forecasts for 2027-2028 case counts found. - Reconciliation unclear between 2,144 vs 2,289 for 2025 final CDC total. - Unclear how "average annual number" will be computed/rounded by resolution source (CDC final vs. provisional data), and whether Pennsylvania deaths/case reclassification disputes affect counts. - No data on whether outbreak acceleration in 2026 is exponential or plateauing into Q4. # Calibration anchors - Kalshi current YES price: **37%** (anchor), up from 28% low, down from 70% high over 40 days — high volatility suggesting thin/uncertain pricing. - Historical precedent: 0/25 years post-elimination exceeded 5,000 cases (peak 1,274 in 2019); required trajectory implies unprecedented ~4.5x sustained multi-year surge, arguing for a probability meaningfully below current market price.

1. **Reference-class error — missing international precedent**: Both forecasts rely solely on the 0/25 US post-2000 base rate but ignore that other countries that lost measles elimination status (e.g., Ukraine, Romania, UK) have had multi-year outbreaks with tens of thousands of annual cases once herd immunity collapsed regionally; the brief explicitly flags "highly likely" loss of elimination status in 2026, which is precisely the trigger event in those foreign analogs, yet neither forecaster incorporates this comparative reference class. 2. **Linear extrapolation instead of epidemic dynamics**: Both forecasts treat the required 2027-28 trajectory as a static multiple of past years ("~5x the record") rather than modeling that measles outbreaks are exponential/compounding — once elimination status is lost and coverage falls below the 92-95% herd-immunity threshold, growth could accelerate super-linearly rather than plateau, understating tail risk. 3. **Resolution-mechanics ambiguity ignored**: The brief notes unresolved discrepancies (2,144 vs 2,289 for 2025) and uncertainty over whether "average annual number" uses CDC final vs. provisional data, plus contested case/death reclassifications (PA deaths excluded from official count) — neither forecaster discounts confidence or widens the range for this resolution-source risk. 4. **Insufficient differentiation from market despite claimed downward adjustment**: Both converge to nearly identical ~27-30% YES, but neither meaningfully explains why the Kalshi price is trending *up* over 30 days (28%→37%, +7%) despite the same historical base-rate argument being available to traders all along — this could reflect information not fully captured in the Aug-2026 cutoff brief (e.g., accelerating Q3/Q4 outbreak news), which both forecasts under-address rather than dismiss as "thin pricing." 5. **Overstated precision on required annual average**: Forecast 2's range (6,600–7,100) versus Forecast 1's (6,500+) both derive from point-projections of 2026 (3,500-4,500), but the brief's own sub-question 2 calculates a wider need (5,670-5,830/year for 2026-28 combined, not just 2027-28) — the two forecasts' arithmetic partially diverges from the brief's own base-case calculation, suggesting under-scrutinized math that should be reconciled before finalizing a probability. 6. **No treatment of policy-driven acceleration scenarios**: The brief cites "absence of Senate-confirmed CDC director," funding cuts, and "mixed HHS/RFK Jr. messaging" as structural, multi-year drivers (not one-off outbreak events), which could sustain elevated transmission across all of 2027-28 rather than a single spike — neither forecaster explicitly weighs this policy persistence as a distinct scenario from "exponential spread," likely underestimating the YES tail.

34% (60% confidence)

Yes: 34% No: 66%

Both forecasts converge at 27–30% YES, but the red-team critique lands two valid points: (1) international analogs (Ukraine, Romania, UK) show that once elimination status is lost — which Lancet/CIDRAP deem 'highly likely' for 2026 — case counts can jump to tens of thousands annually, and (2) the required 2027–28 pace (~6,600/yr) is only ~1.5–1.7x the current 2026 trajectory, not the intimidating '5x the record' framing, given cases roughly doubled from 2025 to 2026. Falling MMR coverage (92.4%), record exemptions, and persistent policy/funding headwinds are structural multi-year drivers, and the market drifting up (28%→37%) may reflect Q3 outbreak momentum beyond the brief's cutoff. Still, no cited projection reaches 5,000+/yr, outbreaks historically saturate in susceptible pockets, and the 0/25 base rate remains strongly adverse, so NO stays favored. I place YES slightly below the Kalshi anchor at 34%, above both forecasts to credit the compounding-growth and elimination-loss tail.

Total pipeline time: 219.4s